Neurocrine Biosciences
NBIX
771 hedge funds and large institutions have $16.9B invested in Neurocrine Biosciences in 2026 Q2 according to their latest regulatory filings, with 147 funds opening new positions, 316 increasing their positions, 225 reducing their positions, and 63 closing their positions.
133% more first-time investments, than exits
New positions opened: 147 | Existing positions closed: 63
40% more repeat investments, than reductions
Existing positions increased: 316 | Existing positions reduced: 225
29% more capital invested
Capital invested by funds: $13.2B → $16.9B (+$3.78B)
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
11% more funds holding
Funds holding: 697 → 771 (+74)
2% more call options, than puts
Call options by funds: $82.8M | Put options by funds: $81.3M
0.37% more ownership
Funds ownership: 99.61% → 99.97% (+0.37%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$142M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$107M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$93.5M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$66.2M |
| 5 |
A
AustralianSuper
Melbourne,
Australia
|
+$51.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$201M |
| 2 |
Millennium Management
New York
|
-$183M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$166M |
| 4 |
Two Sigma Investments
New York
|
-$146M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$100M |
NBIX Hedge Fund Activity: Q2 2026 in Review
771 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q2 2026, worth a combined $16.9B — up 29% from $13.2B a quarter earlier.
Buyers outnumbered sellers: 147 funds opened new NBIX positions and 63 closed out — a net gain of 84 holders — while 316 added to existing stakes and 225 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $142M. The largest seller was Wellington Management Group, cutting an estimated $201M.
- 771 institutional investors held Neurocrine Biosciences (NBIX) as of Q2 2026, up from 697 in Q1 2026.
- Funds reported $16.9B of Neurocrine Biosciences stock for Q2 2026, up 29% quarter-over-quarter.
- 147 funds opened new Neurocrine Biosciences positions in Q2 2026 and 63 closed out, a net change of +84 holders.
- The largest Neurocrine Biosciences buyer in Q2 2026 was JP Morgan Chase, an estimated $142M added.
- The largest Neurocrine Biosciences seller in Q2 2026 was Wellington Management Group, an estimated $201M sold.
Based on aggregated 13F filings for Q2 2026.